U.S. Markets open in 5 hrs 43 mins
  • S&P Futures

    3,796.25
    +2.25 (+0.06%)
     
  • Dow Futures

    30,310.00
    0.00 (0.00%)
     
  • Nasdaq Futures

    11,644.25
    +20.50 (+0.18%)
     
  • Russell 2000 Futures

    1,769.30
    +1.30 (+0.07%)
     
  • Crude Oil

    87.94
    +0.18 (+0.21%)
     
  • Gold

    1,733.00
    +12.20 (+0.71%)
     
  • Silver

    20.75
    +0.21 (+1.00%)
     
  • EUR/USD

    0.9918
    -0.0068 (-0.6843%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    28.68
    -0.39 (-1.34%)
     
  • GBP/USD

    1.1355
    -0.0120 (-1.0446%)
     
  • USD/JPY

    144.6020
    +0.4030 (+0.2795%)
     
  • BTC-USD

    20,211.88
    -56.07 (-0.28%)
     
  • CMC Crypto 200

    459.31
    +0.90 (+0.20%)
     
  • FTSE 100

    7,060.67
    +8.05 (+0.11%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer

·1 min read
  • Innate Pharma SA's (NASDAQ: IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ: AZNdid not meet a pre-defined threshold for efficacy.

  • Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.

  • There were no new safety findings. AstraZeneca plans to share the data in due course.

  • Related: Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity.

  • The INTERLINK-1 study evaluated monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

  • Monalizumab is being studied in a Phase 3 study sponsored by AstraZeneca, evaluating durvalumab in combination with monalizumab or AstraZeneca's oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer.

  • Price Action: IPHA shares are down 16.3% at $2.68 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.